Brief: Hls Therapeutics Announces Qtrly Loss Per Share $0.40

HLS Therapeutics

19/03/2020 10:42

March 19 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FISCAL 2019
FINANCIAL RESULTS
    * HLS THERAPEUTICS INC - QTRLY REVENUES $13.9 MILLION VERSUS
$16.7
MILLION
    * HLS THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.40
    * HLS THERAPEUTICS QTRLY LOSS PER SHARE OF $0.40
    * HLS THERAPEUTICS INC - RECEIVED MEDICAL DEVICE LICENSE
FROM
HEALTH CANADA FOR CSAN PRONTO POINT-OF-CARE BLOOD TESTING
MEDICAL DEVICE
    * HLS THERAPEUTICS INC - RECEIVED APPROVAL FROM HEALTH
CANADA FOR
VASCEPA TO REDUCE RISK OF CARDIOVASCULAR EVENTS
    * HLS THERAPEUTICS - AS AT DEC 31, 2019, COMPANY HAD CASH
AND CASH
EQUIVALENTS OF $47.1 MILLION, UP FROM $10.9 MILLION AT DEC 31,
2018

Source text for Eikon:  ID:nCNW64spka 
Further company coverage:  HLS.TO 

 ((Briefs@thomsonreuters.com;))